Myeloma: diagnosis and management - National Institute for Health and Care Excellence (NICE)
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
- A table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions for patients with myeloma. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details. NICE has also produced a COVID-19 rapid guideline on haematopoietic stem cell transplantation.
In October 2018, we withdrew recommendations on preventing thrombosis because they have been replaced by the NICE guideline on venous thromboembolism in over 16s.